RV6 Stock Overview Charles River Laboratories International, Inc. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Charles River Laboratories International, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Charles River Laboratories International Historical stock prices Current Share Price US$174.90 52 Week High US$251.80 52 Week Low US$163.85 Beta 1.38 1 Month Change -5.79% 3 Month Change -4.95% 1 Year Change -18.08% 3 Year Change -46.02% 5 Year Change 29.56% Change since IPO 548.98%
Recent News & Updates
Independent Director recently sold €1.5m worth of stock Nov 13
Charles River Laboratories International, Inc. Revises Earnings Guidance for Year 2024 Nov 07
Third quarter 2024 earnings released: EPS: US$1.36 (vs US$1.70 in 3Q 2023) Nov 07 Charles River Laboratories International, Inc. Launches New Retrogenix Non-Human Protein Library
Now 20% undervalued after recent price drop Sep 23
Now 20% undervalued after recent price drop Aug 13 See more updates
Independent Director recently sold €1.5m worth of stock Nov 13
Charles River Laboratories International, Inc. Revises Earnings Guidance for Year 2024 Nov 07
Third quarter 2024 earnings released: EPS: US$1.36 (vs US$1.70 in 3Q 2023) Nov 07 Charles River Laboratories International, Inc. Launches New Retrogenix Non-Human Protein Library
Now 20% undervalued after recent price drop Sep 23
Now 20% undervalued after recent price drop Aug 13
Second quarter 2024 earnings released: EPS: US$1.75 (vs US$1.89 in 2Q 2023) Aug 08 Charles River Laboratories International, Inc. (NYSE:CRL) announces an Equity Buyback for $1,000 million worth of its shares.
Now 21% undervalued after recent price drop Jul 19
Charles River Laboratories International, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 17
Charles River Laboratories International, Inc. Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development May 31 Charles River Laboratories International, Inc. Reports Impairment Charges for the First Quarter Ended March 30, 2024 May 12
Charles River Laboratories International, Inc. Reports Unaudited Consolidated Impairment Charges for the First Quarter Ended March 30, 2024
First quarter 2024 earnings released: EPS: US$1.31 (vs US$2.02 in 1Q 2023) May 09
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing Apr 16
Charles River Laboratories International, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 13
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology Apr 12
Charles River Laboratories International, Inc., Annual General Meeting, May 08, 2024 Mar 30
Insider recently sold €1.2m worth of stock Mar 04
Insider recently sold €930k worth of stock Feb 26
Charles River Laboratories International, Inc. (NYSE:CRL) acquired additional 41% stake in Noveprim Limited for approximately $210 million. Feb 15
Full year 2023 earnings released: EPS: US$9.27 (vs US$9.57 in FY 2022) Feb 15
Charles River Laboratories International, Inc. Introduces First Rapid Animal-Free Bacterial Endotoxin Test Jan 29
Charles River Laboratories International, Inc. Appoints Reshema Kemps-Polanco to Board of Directors Jan 25
Charles River Laboratories International, Inc. to Report Q4, 2023 Results on Feb 14, 2024 Jan 24 Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
Now 21% undervalued Jan 17
Charles River Laboratories International, Inc. Introduces Cliniprime Cryopreserved Leukopaks, Expanding Suite of Gmp-Compliant Cellular Products Nov 18
Chairman recently bought €922k worth of stock Nov 16
Third quarter 2023 earnings released: EPS: US$1.70 (vs US$1.90 in 3Q 2022) Nov 09
Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year 2023 Nov 09
Insufficient new directors Nov 01
Charles River Laboratories International, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 17
Charles River Laboratories International, Inc. Unveils Lentivation Platform to Expedite Lvv-Based Gene Therapy Manufacturing Sep 27
Charles River Laboratories International, Inc. Reaffirms Earnings Guidance for the Year 2023 and Provides Revenue Guidance for the Year 2024 Sep 23
Insider recently sold €1.1m worth of stock Aug 16 Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year 2023 Aug 10
Second quarter 2023 earnings released: EPS: US$1.89 (vs US$2.15 in 2Q 2022) Aug 10
Now 20% undervalued Aug 04
Now 21% undervalued Jul 19
Glancy Prongay & Murray LLP Announces Investors with Substantial Losses Have Opportunity to Lead the Securities Fraud Class Action Lawsuit Against Charles River Laboratories International, Inc Jun 24
Charles River Laboratories International, Inc. Launches Off-The-Shelf Lentiviral Vector Packaging Plasmids Jun 14
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Charles River Laboratories International, Inc May 20
Now 18% undervalued after recent price drop May 16
Insider recently sold €170k worth of stock May 16
First quarter 2023 earnings released: EPS: US$2.02 (vs US$1.84 in 1Q 2022) May 12
Charles River Laboratories International, Inc. Revises Earnings Guidance for the Fiscal Year 2023 May 12
Investor sentiment deteriorates as stock falls 16% Mar 13
Independent Director recently bought €365k worth of stock Mar 01
Full year 2022 earnings released: EPS: US$9.57 (vs US$7.77 in FY 2021) Feb 23
Charles River Laboratories Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein Feb 14
Charles River Laboratories International, Inc. to Report Q4, 2022 Results on Feb 22, 2023 Feb 10
Charles River Laboratories International, Inc. (NYSE : CRL) acquired the remaining 80% stake in Samdi Tech, Inc. for $50 million. Jan 31
Charles River Laboratories International, Inc. Announces the Launch of Their New CliniPrimeTM Suite of Good Manufacturing Practice Compliant Cellular Starting Materials Jan 17
Charles River Establishes eXpDNA Plasmid Manufacturing Platform to Expedite DNA Programs Jan 13
Arlington Management Employees, LLC acquired Avian Vaccine Business from Charles River Laboratories International, Inc. (NYSE:CRL). Jan 06
Independent Director recently bought €313k worth of stock Dec 08
Charles River Laboratories International, Inc. Appoints Craig B. Thompson to the Board Dec 08
Charles River Laboratories International, Inc. Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection Dec 03
Insider recently sold €117k worth of stock Nov 09
Now 20% undervalued after recent price drop Nov 03 An unknown buyer entered into a definitive agreement to acquire Avian Vaccine Business from Charles River Laboratories International, Inc. (NYSE:CRL) for approximately $200 million.
Charles River Laboratories International, Inc. Launches Hemacare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research Oct 20
Charles River Laboratories International, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 12
Charles River Launches Naavigation Vector Platform to Accelerate Gene Therapy Programs Oct 11
Investor sentiment improved over the past week Oct 06
Charles River Laboratories International, Inc. Receives Good Manufacturing Practice Certification from European Medicines Agency Aug 10
Second quarter 2022 earnings released: EPS: US$2.15 (vs US$1.76 in 2Q 2021) Aug 04 Charles River Laboratories International, Inc. Revises Revenue Guidance for 2022
Charles River Laboratories International, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 12
First quarter 2022 earnings released: EPS: US$1.84 (vs US$1.23 in 1Q 2021) May 05
Charles River Laboratories International, Inc. Revises Earnings Guidance for 2022 May 05
Charles River Laboratories International, Inc. and Valo Health, Inc. Launch Logica, an Integrated Ai-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets Apr 28
Charles River Laboratories International, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 14
Charles River Laboratories International, Inc. (NYSE : CRL) acquired Explora BioLabs Holdings, Inc. for approximately $300 million. Apr 07
Charles River Laboratories International, Inc. Announces Management Changes Mar 29
Insider recently sold €102k worth of stock Feb 25
Charles River Laboratories International, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022 Feb 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 17
Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year of 2022 Jan 12
Third quarter 2021 earnings released: EPS US$2.05 (vs US$2.07 in 3Q 2020) Nov 04
Chairman recently sold €3.4m worth of stock Aug 11
Charles River Laboratories International, Inc. Increases Earnings Guidance for the Year 2021 Aug 05
Second quarter 2021 earnings released: EPS US$1.76 (vs US$1.36 in 2Q 2020) Aug 05
Charles River Laboratories International, Inc. (NYSE:CRL) completed the acquisition of Vigene Biosciences, Inc.. Jul 01
Charles River Laboratories International, Inc. (NYSE:CRL) signed an agreement to acquire Vigene Biosciences, Inc. for approximately $350 million from Signet Healthcare Partners and others. May 18 Shareholder Returns RV6 DE Life Sciences DE Market 7D -5.6% -2.8% -2.6% 1Y -18.1% -5.9% 6.9%
See full shareholder returns
Return vs Market: RV6 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is RV6's price volatile compared to industry and market? RV6 volatility RV6 Average Weekly Movement 7.6% Life Sciences Industry Average Movement 7.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: RV6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RV6's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Show more Charles River Laboratories International, Inc. Fundamentals Summary How do Charles River Laboratories International's earnings and revenue compare to its market cap? RV6 fundamental statistics Market cap €9.10b Earnings (TTM ) €395.90m Revenue (TTM ) €3.89b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RV6 income statement (TTM ) Revenue US$4.06b Cost of Revenue US$2.61b Gross Profit US$1.45b Other Expenses US$1.04b Earnings US$413.08m
Last Reported Earnings
Sep 28, 2024
Earnings per share (EPS) 8.08 Gross Margin 35.67% Net Profit Margin 10.17% Debt/Equity Ratio 60.1%
How did RV6 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 14:23 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/28 Annual Earnings 2023/12/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Charles River Laboratories International, Inc. is covered by 45 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Toung Argus Research Company Gregory Bolan Avondale Partners Eric Coldwell Baird
Show 42 more analysts 
